Skip Nav Destination
Issues
1 August 2020
-
Cover Image
Cover Image
The cover shows aggregates of immune cells detected in rhabdomyosarcomas, termed tertiary lymphoid structures (TLS). The image depicts fused single chromogenic stains of immune markers clustering in TLS. TIGIT: purple, CD31: red, CD163: white, CSF-1R: yellow, IDO-1: green, CD8: orange, CD4: light blue, CD3: pink. Stem-like T cells reside in these dense antigen-presenting-cell niches within the tumor TLS. TLS are a major player in antitumor immune responses and are organized structures where intratumoral T and B cells are educated to become effector and memory cells capable of recognizing the tumor. For details, see the article by Chen and colleagues on page 4018 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Reviews
Author Choice
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines
Marc Tischkowitz; Sidong Huang; Susana Banerjee; Jennifer Hague; William P.D. Hendricks; David G. Huntsman; Jessica D. Lang; Krystal A. Orlando; Amit M. Oza; Patricia Pautier; Isabelle Ray-Coquard; Jeffrey M. Trent; Michael Witcher; Leora Witkowski; W. Glenn McCluggage; Douglas A. Levine; William D. Foulkes; Bernard E. Weissman
Clinical Trials: Targeted Therapy
Author Choice
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd; Richard R. Furman; Steven E. Coutre; Ian W. Flinn; Jan A. Burger; Kristie Blum; Jeff P. Sharman; William Wierda; Weiqiang Zhao; Nyla A. Heerema; Ying Luan; Emily A. Liu; James P. Dean; Susan O'Brien
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Amanda N. Fader; Dana M. Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M. O'Malley; Floor J. Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E. Schwartz; Alessandro D. Santin
Author Choice
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Debashis Sarker; Ruth Plummer; Tim Meyer; Mikael H. Sodergren; Bristi Basu; Cheng Ean Chee; Kai-Wen Huang; Daniel H. Palmer; Yuk Ting Ma; T.R. Jeff Evans; Duncan R.C. Spalding; Madhava Pai; Rohini Sharma; David J. Pinato; James Spicer; Sarah Hunter; Vineet Kwatra; Joanna P. Nicholls; David Collin; Robert Nutbrown; Helen Glenny; Sonia Fairbairn; Vikash Reebye; Jon Voutila; Stephanie Dorman; Pinelopi Andrikakou; Peter Lloyd; Steve Felstead; Jenni Vasara; Robert Habib; Chris Wood; Pal Saetrom; Hans E. Huber; David C. Blakey; John J. Rossi; Nagy Habib
Author Choice
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Lillian M. Smyth; Kenji Tamura; Mafalda Oliveira; Eva M. Ciruelos; Ingrid A. Mayer; Marie-Paule Sablin; Laura Biganzoli; Helen J. Ambrose; Jack Ashton; Alan Barnicle; Des D. Cashell; Claire Corcoran; Elza C. de Bruin; Andrew Foxley; Joana Hauser; Justin P.O. Lindemann; Rhiannon Maudsley; Robert McEwen; Michele Moschetta; Martin Pass; Vicky Rowlands; Gaia Schiavon; Udai Banerji; Maurizio Scaltriti; Barry S. Taylor; Sarat Chandarlapaty; José Baselga; David M. Hyman
Author Choice
Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Kenneth R. Gundle; Gary B. Deutsch; Howard J. Goodman; Seth M. Pollack; Matthew J. Thompson; Jessica L. Davis; Mee-Young Lee; Daniel C. Ramirez; William Kerwin; Jessica A. Bertout; Marc O. Grenley; Kimberly H.W. Sottero; Emily Beirne; Jason Frazier; Joyoti Dey; Micah Ellison; Richard A. Klinghoffer; Robert G. Maki
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma
Sikander Ailawadhi; Rachael Sexton; Suzanne Lentzsch; Muneer H. Abidi; Peter M. Voorhees; Adam D. Cohen; Eric M. Rohren; Stephen Heitner; Kevin Kelly; Niklas J. Mackler; David M. Baer; Antje Hoering; Brian Durie; Robert Z. Orlowski
Clinical Trials: Immunotherapy
Author Choice
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi; Yaoping Shi; Ahmed O. Kaseb; Xingxing Qi; Yuan Zhang; Jiachang Chi; Qing Lu; Huiping Gao; Hua Jiang; Huamao Wang; Daijing Yuan; Hong Ma; Hongyang Wang; Zonghai Li; Bo Zhai
Precision Medicine and Imaging
First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma
Kim S. de Valk; Marion M. Deken; Henricus J.M. Handgraaf; Shadhvi S. Bhairosingh; Okker D. Bijlstra; Michiel J. van Esdonk; Anton G.T. Terwisscha van Scheltinga; A. Rob P.M. Valentijn; Taryn L. March; Jaap Vuijk; Koen C.M.J. Peeters; Fabian A. Holman; Denise E. Hilling; J. Sven D. Mieog; John V. Frangioni; Jacobus Burggraaf; Alexander L. Vahrmeijer
Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Xiaoju Max Ma; Johanna C. Bendell; Herbert I. Hurwitz; Christine Ju; John J. Lee; Alex Lovejoy; Christoph Mancao; Alan Nicholas; Richard Price; Nicolas Sommer; Nalin Tikoo; Lijing Yao; Stephanie J. Yaung; John F. Palma
Author Choice
The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
Lingling Chen; Teniola Oke; Nicholas Siegel; Gady Cojocaru; Ada J. Tam; Richard L. Blosser; Jessica Swailes; John A. Ligon; Andriana Lebid; Carol Morris; Adam Levin; Daniel S. Rhee; Fabian M. Johnston; Jonathan B. Greer; Christian F. Meyer; Brian H. Ladle; Elizabeth D. Thompson; Elizabeth A. Montgomery; Woonyoung Choi; David J. McConkey; Robert A. Anders; Drew M. Pardoll; Nicolas J. Llosa
Author Choice
Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Sheila Weinmann; Michael C. Leo; Melanie Francisco; Charisma L. Jenkins; Todd Barry; Glen Leesman; Steven P. Linke; Pat W. Whitworth; Rakesh Patel; James Pellicane; Fredrik Wärnberg; Troy Bremer
Translational Cancer Mechanisms and Therapy
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Jenny H. Lee; Alexander M. Menzies; Matteo S. Carlino; Ashleigh C. McEvoy; Shahneen Sandhu; Alison M. Weppler; Russell J. Diefenbach; Sarah-Jane Dawson; Richard F. Kefford; Michael J. Millward; Zeyad Al-Ogaili; Thien Tra; Elin S. Gray; Stephen Q. Wong; Richard A. Scolyer; Georgina V. Long; Helen Rizos
Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Alissa J. Cooper; Yoshihisa Kobayashi; Dewey Kim; Sarah E. Clifford; Sasha Kravets; Suzanne E. Dahlberg; Emily S. Chambers; Jiaqi Li; Deepa Rangachari; Tom Nguyen; Daniel B. Costa; Michael S. Rabin; Nikhil Wagle; Lynette M. Sholl; Pasi A Jänne; Geoffrey R. Oxnard
Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma
Flor Mendez; Padma Kadiyala; Felipe J. Nunez; Stephen Carney; Fernando M. Nunez; Jessica C. Gauss; Ramya Ravindran; Sheeba Pawar; Marta Edwards; Maria Belen Garcia-Fabiani; Santiago Haase; Pedro R. Lowenstein; Maria G. Castro
Author Choice
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Jarle Bruun; Kushtrim Kryeziu; Peter W. Eide; Seyed H. Moosavi; Ina A. Eilertsen; Jonas Langerud; Bård Røsok; Max Z. Totland; Tuva H. Brunsell; Teijo Pellinen; Jani Saarela; Christian H. Bergsland; Hector G. Palmer; Kristoffer W. Brudvik; Tormod Guren; Rodrigo Dienstmann; Marianne G. Guren; Arild Nesbakken; Bjørn Atle Bjørnbeth; Anita Sveen; Ragnhild A. Lothe
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer
James R. Whittle; François Vaillant; Elliot Surgenor; Antonia N. Policheni; Göknur Giner; Bianca D. Capaldo; Huei-Rong Chen; He K. Liu; Johanna F. Dekkers; Norman Sachs; Hans Clevers; Andrew Fellowes; Thomas Green; Huiling Xu; Stephen B. Fox; Marco J. Herold; Gordon K. Smyth; Daniel H.D. Gray; Jane E. Visvader; Geoffrey J. Lindeman
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
Biagio Ricciuti; Gonzalo Recondo; Liam F. Spurr; Yvonne Y. Li; Giuseppe Lamberti; Deepti Venkatraman; Renato Umeton; Andrew D. Cherniack; Mizuki Nishino; Lynette M. Sholl; Geoffrey I. Shapiro; Mark M. Awad; Michael L. Cheng
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer
Paymaneh D. Malihi; Ryon P. Graf; Angel Rodriguez; Naveen Ramesh; Jerry Lee; Ramsay Sutton; Rhett Jiles; Carmen Ruiz Velasco; Emi Sei; Anand Kolatkar; Christopher Logothetis; Nicholas E. Navin; Paul Corn; Ana M. Aparicio; Ryan Dittamore; James Hicks; Peter Kuhn; Amado J. Zurita
Author Choice
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
Matthew A. Lakins; Alexander Koers; Raffaella Giambalvo; Jose Munoz-Olaya; Robert Hughes; Emma Goodman; Sylwia Marshall; Francisca Wollerton; Sarah Batey; Daniel Gliddon; Mihriban Tuna; Neil Brewis
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.